Special Issue "Screening and Genetic Characterization of Colorectal Cancer: A Multi-Step Approach"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 June 2021).

Special Issue Editors

Dr. Silvia Sanduleanu
E-Mail Website
Guest Editor
University Hospital Maastricht, Maastricht, Netherlands
Interests: Colorectal cancer; screening; clinical diagnosis; endoscopic imagining and (endoscopic) treatment; Clinical biomarkers of colorectal cancer; Inflammatory bowel disease and colorectal cancer
Dr. Giovanni Crisafulli
E-Mail Website
Guest Editor
1. Department of Oncology, University of Torino, 10060 Candiolo (TO), Italy
2. Candiolo Cancer Institute, FPO–IRCCS, 10060 Candiolo (TO), Italy
Interests: Genetics; Liquid Biopsy; Tumour Heterogeneity, Clonal Evolution; Bioinformatics; Colorectal Cancers

Special Issue Information

Colorectal cancer (CRC) is a largely preventable genetic disease, with well-established population-based organized screening programs and structured opportunistic screening in many countries across the world. Despite strong evidence that screening can reduce CRC incidence and mortality, wide variation still exists in the status, strategy, and effectiveness of the implementation of CRC screening efforts worldwide. When the tumor is identified, different advanced genetic approaches can be applied for its characterization. These approaches are relevant for patient stratification and the guidance of therapy in the precision oncology era. However, economic resources, healthcare structure, and infrastructure vary in their support of screening and precision oncology, guided by the advanced genetic characterization of the tumor. In addition, the COVID-19 pandemic has had a significant impact on screening and can enhance existing disparities. Many CRC screening and advanced genetic approaches that depend on research activities have been reduced or temporarily shut down during the pandemic, leading to a significant increase in cancer incidence and treatment delays. Because of the unknown timeline of the pandemic, this disruption may, in turn, decrease patient motivation to participate in screening or therapy.

This Special Issue presents a brief overview of CRC burden and the activity of genetic characterization, with a particular focus on challenges in the post-COVID-19 world. We address current trends in CRC screening/advanced genetic characterization and propose solutions to potential barriers.

Dr. Giovanni Crisafulli
Guest Editor

Dr. Silvia Sanduleanu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • colorectal cancer
  • screening
  • prevention
  • COVID-19

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series
Cancers 2021, 13(15), 3673; https://doi.org/10.3390/cancers13153673 - 22 Jul 2021
Viewed by 268
Introduction: Abdominal desmoid tumors are locally aggressive tumors that develop in familial adenomatous polyposis (FAP) patients, within the mesentery or abdominal wall. The understanding and implications of the treatment regimens are evolving. Aim: To assess the course, treatment, and outcomes of FAP and [...] Read more.
Introduction: Abdominal desmoid tumors are locally aggressive tumors that develop in familial adenomatous polyposis (FAP) patients, within the mesentery or abdominal wall. The understanding and implications of the treatment regimens are evolving. Aim: To assess the course, treatment, and outcomes of FAP and non-FAP abdominal desmoids and their related genetic alterations. Methods: Retrospective cohort study. Demographics, tumor characteristics, oncological and surgical history, complications, genetic-testing, and mortality data were retrieved from two tertiary referral centers. Results: Sixty-two patients were identified (46 FAP and 16 non-FAP). Thirty-eight patients (61.3%) underwent surgical procedures (12 urgent and 26 elective). Out of 33 tumor resections, 39.4% recurred. Hormonal therapy, COX-inhibitors, chemotherapy, imatinib, and sorafenib were used in 35 (56.4%), 30 (48.4%), 18 (29.1%), 7 (11.3%), and 8 (12.9%) of patients, respectively, with a 2 year progression-free survival of 67.8%, 57.7%, 38.4%, and 28.5%, respectively. Forty-one patients (66.1%) suffered complications: bowel obstruction (30.6%), hyperalimentation (14.5%), ureteral obstruction (12.9%), perforation (11.3%), abscess formation (3.2%), and spinal cord compression (3.2%). Non-FAP patients carried pathogenic mutations in CHEK2, BLM, ERCC5, MSH6, and PALB2. Conclusions: Abdominal desmoids are mostly FAP-related and are associated with severe outcomes. We also report a group of non-FAP abdominal desmoids, which includes patients with additional cancer-related gene alterations. This interesting group should be further explored. Full article
Show Figures

Graphical abstract

Back to TopTop